Consumers and health professionals are advised that Apotex, in consultation with the TGA, is recalling one batch of APO-Cabergoline 500 mcg tablets due to a packaging issue which could potentially lead to the product degrading over time in moist conditions.
APO-Cabergoline is a medicine used to prevent the production of breast milk in women after giving birth, or to treat abnormally high levels of prolactin.
The affected batch is MK0903, with an expiry date of February 2017. The batch number is displayed on the bottom flap of the carton as well as on the side of the bottle label.
Information for consumers
If you, or someone you provide care for, use APO-Cabergoline please check the batch number displayed on the bottle label or the base of the carton.
If the product is from batch MK0903, please return it to the pharmacy where it was purchased for a refund or a replacement product.
If you have any concerns or queries, speak to your health professional or contact Apotex Medical Information on 1800 195 055.
Information for health professionals
Apotex has written to pharmacists providing more details about this issue and the recall procedure.
If you are treating a patient who is using APO-Cabergoline 500 mcg tablets please alert them to this issue. If they have tablets from the affected batch (MK0903) advise them to return it to the dispensing pharmacy for a refund or a replacement product.
If you have any questions about this issue or the recall procedure, contact Apotex customer service on 1800 276 839.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine or vaccine.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.